. 2017 Mar 1;9(3-4):73–80. doi: 10.1177/1756287217697661

Table 3.

Benefits of adding neo(adjuvant) ADT to radiation therapy.

Trial	Duration of neo(adjuvant) ADT	Number of patients	Population	Radiation therapy dose	Median follow up	10-year OS
RTOG 8531¹⁶	Until disease progression	977	cT1–2 N1 M0 or cT3–4 N0–1 M0 or pT3 after RP	44–46 Gy + 21–24 Gy boost to the prostatic bed	7.6 years	49%
EORTC 22863¹⁷	Groserlin 3 years Ciproterone 1 month	415	T1–2 grade 3 M0 or T3–4 N0–1 M0	50 Gy + 20 Gy boost to prostate and SV	9.1 years	58%
EPCP¹⁸	ND	1370	T1–4 Nx-1 M0	64 Gy	7.2 years	ND
TROG 9601¹⁹	3–6 months	818	T2b–4 N0 M0	66 Gy to prostate and SV	5.9 years	ND
RTOG 8610²⁰	2 months	456	T2–4 N0-x M0	44–46 Gy to whole pelvis + 21–24 Gy boost to prostate	12.6 years	43%
D’Amico et al.²¹	6 months	206	T1b–2b N0 M0	ND	7.6 years	~40%

ADT, androgen deprivation therapy; EPCP, Early Prostate Cancer Programme; ND, not determined; OS, overall survival; RP, radical prostatectomy; RTOG, Radiation Therapy Oncology Group; SV, seminal vesicle; TROG, Trans-Tasman Radiation Oncology Group.